Array Biopharma Inc (ARRY) 4.06 $ARRY
Array BioPharma To Present At The Bank of America Merrill Lynch Healthcare Conference and the UBS Global Healthcare Conference
PR Newswire - Mon May 12, 11:00AM CDT
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas and the UBS Global Healthcare Conference in New York City. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website: www.arraybiopharma.com.
Top Gainers Technical Data -- Research on BioScrip, Medivation, Array BioPharma, and Doral Financial
PR Newswire - Mon May 12, 7:17AM CDT
The US markets saw a positive sentiment on Friday, May 09, 2014, with the NASDAQ Composite closing at 4,071.87, up 0.50%, the Dow Jones Industrial Average ending the session at 16,583.34, up 0.20% and the S&P 500 edging 0.15% higher to finish the trading session at 1,878.48. The session saw a positive impact from Consumer Discretionary, Health Care and Consumer Staples sectors along with a drag from Financials, Energy and Utilities sectors. A number of stocks saw large movements, including BioScrip Inc. (NASDAQ: BIOS), Medivation Inc. (NASDAQ: MDVN), Array BioPharma Inc. (NASDAQ: ARRY) and Doral Financial Corporation (NYSE: DRL). Free technical research on BIOS, MDVN, ARRY and DRL can be downloaded upon signing up at:
Array Biopharma Up 6.6%, Shares Break Through Resistance (ARRY)
Comtex SmarTrend(R) - Fri May 09, 11:41AM CDT
Array Biopharma (NASDAQ:ARRY) is one of today's best performing low-priced stocks, up 6.6% to $3.89 on 1.1x average daily volume. Array Biopharma has traded 2.2 million shares thus far today, vs. average volume of 1.9 million shares per day. The stock has outperformed the Dow (6.6% to the Dow's -0.0%) and outperformed the S&P 500 (6.6% to the S&P's -0.2%) during today's trading.
Refractory Multiple Myeloma - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r636v2/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Eli Lilly and Company - Exelixis, Inc. - Genentech, Inc. - GlaxoSmithKline plc - Incyte Corporation - Janssen Biotech, Inc. - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Sanofi - Senesco Technologies, Inc. - Senhwa Biosciences Drug Profiles: - ixazomib citrate - panobinostat - carfilzomib - elotuzumab - plitidepsin - bendamustine - ibrutinib - ruxolitinib phosphate - ARRY-520 - ALT-801 - pomalidomide - chloroquine [bortezomib] [cyclophosphamide] - Melflufen - Circularly Permuted TRAIL - alisertib - daratumumab - PRLX-93936 - carfilzomib - cabozantinib (s)-malate - SNS-01T - SL-401 - TH-302 - P-276 - MOR-202 - KW-2478 - palbociclib - luminespib - plerixafor - ricolinostat - LY-2812176 For more information visit http://www.researchandmarkets.com/research/r636v2/refractory
Metastatic Breast Cancer - Pipeline Review, H1 2014: 83 Companies Profile
M2 - Thu May 08, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2bjnnz/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Adherex Technologies Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Agonox - AlphaMab Co., Ltd - Amarna Therapeutics B.V. - Amgen Inc. - Aphios Corporation - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - Bavarian Nordic A/S - BioMarin Pharmaceutical Inc. - BioNumerik Pharmaceuticals, Inc. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cell Therapeutics, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Corcept Therapeutics Incorporated - Curadis GmbH - Curaxys, S.L. - Dainippon Sumitomo Pharma Co., Ltd. - Dompe Farmaceutici S.p.A. - EirGen Pharma Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. and much more... For more information visit http://www.researchandmarkets.com/research/2b...tic_breast
Allergic Rhinitis Therapeutics Pipeline Review 2014 - Analysis of 35 Companies & 54 Drug Profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zkn5w5/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Genentech, Inc. - Nektar Therapeutics - BioTech Tools - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - ALK-Abello A/S - Mitsubishi Tanabe Pharma Corporation - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Revance Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Array BioPharma Inc. - Stallergenes S.A. - Cytos Biotechnology AG - Allergopharma Joachim Ganzer KG - Respiratorius AB - AnaptysBio, Inc. - Oxagen Limited - Axikin Pharmaceuticals, Inc. - VentiRx Pharmaceuticals, Inc. - Laboratorios LETI S.L. - Celsus Therapeutics Plc - KAEL-GemVax Co., Ltd. - GlycoMar Limited - Fountain Biopharma Inc. - Ampio Pharmaceuticals, Inc. - Rottapharm|Madaus For more information visit http://www.researchandmarkets.com/research/zk...c_rhinitis
Inflammatory Pain - Pipeline Review, H1 2014: 43 Company and 68 Drug Profiled
M2 - Wed May 07, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zxzwlh/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - A2M Pharma GmbH - AbbVie Inc. - Adynxx, Inc. - AnaMar AB - Anavex Life Sciences Corp. - AngioChem Inc. - Aniona ApS - Array BioPharma Inc. - Asahi Kasei Pharma Corp. - AskAt Inc. - AstraZeneca PLC - Biousian Biosystems, Inc. - Boehringer Ingelheim GmbH - CLL Pharma - DiverDrugs, S.L. - Evotec AG - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Hydra Biosciences, Inc. - RaQualia Pharma Inc. - Relevare Pharmaceuticals Ltd. - Shionogi & Co., Ltd. - Sunovion Pharmaceuticals Inc. - Takeda Pharmaceutical Company Limited - Theralpha SAS - Upsher-Smith Laboratories, Inc. - Winston Pharmaceuticals, Inc. - Zalicus Inc. - Ziarco Pharma Ltd Drug Profiles: - minocycline - grapiprant - AN-721 - ZPL-3893787 - Z-944 - lidocaine - S-120083 - SYN-1002 - Small Molecule To Antagonise P2X3 and P2X2/3 - OX-MPI - nNOS/iNOS - HC-030031 - zucapsaicin - TrkA Program - ANAVEX-1079 - ANG-2002 - AMAP-102 - RQ-00000008 - GBR-900 - CDK9 Inhibitors - Neu-P12 - CNSB-002 - CNSB-006 - AK-106 - Z-212 - PLX Cells For Neuropathic And Inflammatory Pain - THA-902 - Conolidine - AYX-3 - Project MITRA For more information visit http://www.researchandmarkets.com/research/zx...atory_pain
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2014
PR Newswire - Tue Apr 29, 7:00AM CDT
Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the third quarter of its fiscal year ending June 30, 2014.
Charles M. Baum, M.D., PH.D. Joins Array BioPharma Board Of Directors
PR Newswire - Mon Apr 28, 3:00PM CDT
Array BioPharma Inc. (NASDAQ: ARRY) today announced that as part of its continued evolution toward late-stage development and commercialization, Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer of Mirati Therapeutics, joined the company's board of directors, effective April 25, 2014.
Global Osteoarthritis Pain Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r39xgv/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Johnson & Johnson - Allergan, Inc. - Sanofi - Eli Lilly and Company - BioDelivery Sciences International, Inc. - Purdue Pharma L.P. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - Addex Therapeutics - Nuvo Research Inc. - Elite Pharmaceuticals, Inc. - Pozen, Inc. - Array BioPharma Inc. - Futura Medical plc - Transition Therapeutics Inc. - AcurePharma AB - Palau Pharma, S.A. - Neurotune AG - QRxPharma Limited - Iroko Pharmaceuticals, LLC - Winston Pharmaceuticals, Inc. - Antibe Therapeutics, Inc. - Flexion Therapeutics, Inc. - AllTranz, Inc. - Afferent Pharmaceuticals, Inc. - iCeutica, Inc. - Rottapharm|Madaus - Theralpha SAS - Creabilis SA - AbbVie Inc. - ARTYX Pharmaceuticals, Inc. - Akron Molecules GmbH Drug Profiles - hydrocodone bitartrate ER - duloxetine hydrochloride DR - buprenorphine hydrochloride - meloxicam nanoformulation - zucapsaicin - diclofenac nanoformulation - ART-144 - (oxycodone naltrexone) - ARRY-797 - (morphine oxycodone) CR - AF-219 - onabotulinumtoxinA - SAR-292833 - ABT-652 - fasitibant chloride - FX-005 - LY-2828360 - triamcinolone acetonide SR - naproxen nanoformulation - OLT-1177 - grapiprant - V-116517 - AKR-202 - (lidocaine tetracaine) - dimiracetam - PA-65020 - mavatrep - AKR-203 - ADX-71943 - TASS For more information visit http://www.researchandmarkets.com/research/r3...oarthritis
Stock to Watch: Array Biopharma Up 7.6% (ARRY)
Comtex SmarTrend(R) - Thu Apr 24, 11:40AM CDT
Array Biopharma (NASDAQ:ARRY) is one of today's best performing low-priced stocks, up 7.6% to $4.09 on 1.2x average daily volume. Array Biopharma has traded 2.0 million shares thus far today, vs. average volume of 1.7 million shares per day. The stock has outperformed the Dow (7.6% to the Dow's 0.1%) and outperformed the S&P 500 (7.6% to the S&P's 0.3%) during today's trading.
Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2014 On April 29, 2014
PR Newswire - Wed Apr 23, 5:30PM CDT
Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2014 and hold a conference call to discuss those results on Tuesday, April 29, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.
Binimetinib Continues To Advance In Clinical Development
PR Newswire - Wed Apr 23, 12:22PM CDT
Following the recent announcement by Novartis and GlaxoSmithKline that they have entered into a definitive agreement to exchange certain assets, Array BioPharma Inc. (NASDAQ: ARRY) reports that Novartis has indicated that it will continue to honor its obligations under the Array-Novartis agreement relating to binimetinib (MEK162), including obligations relating to support for ongoing clinical trials as specified in the agreement.
Investors look to Lighten Up on Shares of Array Biopharma, Shares Down 7.2% (ARRY)
Comtex SmarTrend(R) - Tue Apr 15, 12:48PM CDT
Array Biopharma (NASDAQ:ARRY) is one of today's worst performing low-priced stocks, down 7.2% to $3.47 on 1.0x average daily volume. Array Biopharma has traded 1.6 million shares thus far today, vs. average volume of 1.6 million shares per day. The stock has underperformed the Dow (-7.2% to the Dow's -0.2%) and underperformed the S&P 500 (-7.2% to the S&P's -0.2%) during today's trading.
Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfizer, Cytokinetics, Portola Pharmaceuticals, Volcano, and Array BioPharma
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Cytokinetics, Incorporated (NASDAQ: CYTK), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), Volcano Corporation (NASDAQ: VOLC), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Hot Stock: Array Biopharma, Shares Drop 5.7% (ARRY)
Comtex SmarTrend(R) - Fri Apr 04, 12:45PM CDT
Array Biopharma (NASDAQ:ARRY) is one of today's worst performing low-priced stocks, down 5.7% to $4.14 on 1.2x average daily volume. Thus far today, Array Biopharma has traded 1.8 million shares, vs. average volume of 1.4 million shares per day. The stock has underperformed the Dow (-5.7% to the Dow's -0.5%) and underperformed the S&P 500 (-5.7% to the S&P's -0.8%) during today's trading.
Biotech Stocks Analysis -- Research on Array BioPharma, ACADIA Pharma, Pharmacyclics, and Isis Pharma
PR Newswire - Fri Mar 28, 5:40AM CDT
On Wednesday, March 26, 2014, the NASDAQ Composite ended at 4,173.58, down 1.43%, the Dow Jones Industrial Average fell 0.60% to 16,268.99, and the S&P 500 closed at 1,852.56, down 0.70%. The losses were broad based as nine out of 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 672.05, up 0.05%, and the same has gained 4.63% in the last three months. Investor-Edge has initiated coverage on the following equities: Array BioPharma Inc. (NASDAQ: ARRY), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free technical research on ARRY, ACAD, PCYC and ISIS can be downloaded upon signing up at:
Stock to Watch: Array Biopharma Down 5.2% (ARRY)
Comtex SmarTrend(R) - Thu Mar 27, 12:46PM CDT
Array Biopharma (NASDAQ:ARRY) is one of today's worst performing low-priced stocks, down 5.2% to $4.54 on 1.3x average daily volume. Array Biopharma has traded 1.7 million shares thus far today, vs. average volume of 1.3 million shares per day. The stock has underperformed the Dow (-5.2% to the Dow's -0.1%) and underperformed the S&P 500 (-5.2% to the S&P's -0.3%) during today's trading.
Price Movements, Clinical Trial Results, and Solid Financial Reports - Analyst Notes on Pfizer, Dendreon, DepoMed, Globus Medical, and Array
PR Newswire - Wed Mar 05, 12:13PM CST
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Dendreon Corp. (NASDAQ: DNDN), DepoMed Inc. (NASDAQ: DEPO), Globus Medical, Inc. (NYSE: GMED), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with TDM-1 in Patients with Metastatic HER2+ Breast Cancer
PR Newswire - Thu Feb 20, 7:00AM CST
Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla® (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.
Array BioPharma To Present At The Bank of America Merrill Lynch Healthcare Conference and the UBS Global Healthcare Conference
PR Newswire - Mon May 12, 11:00AM CDT
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas and the UBS Global Healthcare Conference in New York City. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website: www.arraybiopharma.com.
Top Gainers Technical Data -- Research on BioScrip, Medivation, Array BioPharma, and Doral Financial
PR Newswire - Mon May 12, 7:17AM CDT
The US markets saw a positive sentiment on Friday, May 09, 2014, with the NASDAQ Composite closing at 4,071.87, up 0.50%, the Dow Jones Industrial Average ending the session at 16,583.34, up 0.20% and the S&P 500 edging 0.15% higher to finish the trading session at 1,878.48. The session saw a positive impact from Consumer Discretionary, Health Care and Consumer Staples sectors along with a drag from Financials, Energy and Utilities sectors. A number of stocks saw large movements, including BioScrip Inc. (NASDAQ: BIOS), Medivation Inc. (NASDAQ: MDVN), Array BioPharma Inc. (NASDAQ: ARRY) and Doral Financial Corporation (NYSE: DRL). Free technical research on BIOS, MDVN, ARRY and DRL can be downloaded upon signing up at:
Array Biopharma Up 6.6%, Shares Break Through Resistance (ARRY)
Comtex SmarTrend(R) - Fri May 09, 11:41AM CDT
Array Biopharma (NASDAQ:ARRY) is one of today's best performing low-priced stocks, up 6.6% to $3.89 on 1.1x average daily volume. Array Biopharma has traded 2.2 million shares thus far today, vs. average volume of 1.9 million shares per day. The stock has outperformed the Dow (6.6% to the Dow's -0.0%) and outperformed the S&P 500 (6.6% to the S&P's -0.2%) during today's trading.
Refractory Multiple Myeloma - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r636v2/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Eli Lilly and Company - Exelixis, Inc. - Genentech, Inc. - GlaxoSmithKline plc - Incyte Corporation - Janssen Biotech, Inc. - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Sanofi - Senesco Technologies, Inc. - Senhwa Biosciences Drug Profiles: - ixazomib citrate - panobinostat - carfilzomib - elotuzumab - plitidepsin - bendamustine - ibrutinib - ruxolitinib phosphate - ARRY-520 - ALT-801 - pomalidomide - chloroquine [bortezomib] [cyclophosphamide] - Melflufen - Circularly Permuted TRAIL - alisertib - daratumumab - PRLX-93936 - carfilzomib - cabozantinib (s)-malate - SNS-01T - SL-401 - TH-302 - P-276 - MOR-202 - KW-2478 - palbociclib - luminespib - plerixafor - ricolinostat - LY-2812176 For more information visit http://www.researchandmarkets.com/research/r636v2/refractory
Metastatic Breast Cancer - Pipeline Review, H1 2014: 83 Companies Profile
M2 - Thu May 08, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2bjnnz/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Adherex Technologies Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Agonox - AlphaMab Co., Ltd - Amarna Therapeutics B.V. - Amgen Inc. - Aphios Corporation - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - Bavarian Nordic A/S - BioMarin Pharmaceutical Inc. - BioNumerik Pharmaceuticals, Inc. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cell Therapeutics, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Corcept Therapeutics Incorporated - Curadis GmbH - Curaxys, S.L. - Dainippon Sumitomo Pharma Co., Ltd. - Dompe Farmaceutici S.p.A. - EirGen Pharma Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. and much more... For more information visit http://www.researchandmarkets.com/research/2b...tic_breast
Allergic Rhinitis Therapeutics Pipeline Review 2014 - Analysis of 35 Companies & 54 Drug Profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zkn5w5/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Genentech, Inc. - Nektar Therapeutics - BioTech Tools - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - ALK-Abello A/S - Mitsubishi Tanabe Pharma Corporation - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Revance Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Array BioPharma Inc. - Stallergenes S.A. - Cytos Biotechnology AG - Allergopharma Joachim Ganzer KG - Respiratorius AB - AnaptysBio, Inc. - Oxagen Limited - Axikin Pharmaceuticals, Inc. - VentiRx Pharmaceuticals, Inc. - Laboratorios LETI S.L. - Celsus Therapeutics Plc - KAEL-GemVax Co., Ltd. - GlycoMar Limited - Fountain Biopharma Inc. - Ampio Pharmaceuticals, Inc. - Rottapharm|Madaus For more information visit http://www.researchandmarkets.com/research/zk...c_rhinitis
Inflammatory Pain - Pipeline Review, H1 2014: 43 Company and 68 Drug Profiled
M2 - Wed May 07, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zxzwlh/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - A2M Pharma GmbH - AbbVie Inc. - Adynxx, Inc. - AnaMar AB - Anavex Life Sciences Corp. - AngioChem Inc. - Aniona ApS - Array BioPharma Inc. - Asahi Kasei Pharma Corp. - AskAt Inc. - AstraZeneca PLC - Biousian Biosystems, Inc. - Boehringer Ingelheim GmbH - CLL Pharma - DiverDrugs, S.L. - Evotec AG - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Hydra Biosciences, Inc. - RaQualia Pharma Inc. - Relevare Pharmaceuticals Ltd. - Shionogi & Co., Ltd. - Sunovion Pharmaceuticals Inc. - Takeda Pharmaceutical Company Limited - Theralpha SAS - Upsher-Smith Laboratories, Inc. - Winston Pharmaceuticals, Inc. - Zalicus Inc. - Ziarco Pharma Ltd Drug Profiles: - minocycline - grapiprant - AN-721 - ZPL-3893787 - Z-944 - lidocaine - S-120083 - SYN-1002 - Small Molecule To Antagonise P2X3 and P2X2/3 - OX-MPI - nNOS/iNOS - HC-030031 - zucapsaicin - TrkA Program - ANAVEX-1079 - ANG-2002 - AMAP-102 - RQ-00000008 - GBR-900 - CDK9 Inhibitors - Neu-P12 - CNSB-002 - CNSB-006 - AK-106 - Z-212 - PLX Cells For Neuropathic And Inflammatory Pain - THA-902 - Conolidine - AYX-3 - Project MITRA For more information visit http://www.researchandmarkets.com/research/zx...atory_pain
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2014
PR Newswire - Tue Apr 29, 7:00AM CDT
Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the third quarter of its fiscal year ending June 30, 2014.
Charles M. Baum, M.D., PH.D. Joins Array BioPharma Board Of Directors
PR Newswire - Mon Apr 28, 3:00PM CDT
Array BioPharma Inc. (NASDAQ: ARRY) today announced that as part of its continued evolution toward late-stage development and commercialization, Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer of Mirati Therapeutics, joined the company's board of directors, effective April 25, 2014.
Global Osteoarthritis Pain Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r39xgv/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Johnson & Johnson - Allergan, Inc. - Sanofi - Eli Lilly and Company - BioDelivery Sciences International, Inc. - Purdue Pharma L.P. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - Addex Therapeutics - Nuvo Research Inc. - Elite Pharmaceuticals, Inc. - Pozen, Inc. - Array BioPharma Inc. - Futura Medical plc - Transition Therapeutics Inc. - AcurePharma AB - Palau Pharma, S.A. - Neurotune AG - QRxPharma Limited - Iroko Pharmaceuticals, LLC - Winston Pharmaceuticals, Inc. - Antibe Therapeutics, Inc. - Flexion Therapeutics, Inc. - AllTranz, Inc. - Afferent Pharmaceuticals, Inc. - iCeutica, Inc. - Rottapharm|Madaus - Theralpha SAS - Creabilis SA - AbbVie Inc. - ARTYX Pharmaceuticals, Inc. - Akron Molecules GmbH Drug Profiles - hydrocodone bitartrate ER - duloxetine hydrochloride DR - buprenorphine hydrochloride - meloxicam nanoformulation - zucapsaicin - diclofenac nanoformulation - ART-144 - (oxycodone naltrexone) - ARRY-797 - (morphine oxycodone) CR - AF-219 - onabotulinumtoxinA - SAR-292833 - ABT-652 - fasitibant chloride - FX-005 - LY-2828360 - triamcinolone acetonide SR - naproxen nanoformulation - OLT-1177 - grapiprant - V-116517 - AKR-202 - (lidocaine tetracaine) - dimiracetam - PA-65020 - mavatrep - AKR-203 - ADX-71943 - TASS For more information visit http://www.researchandmarkets.com/research/r3...oarthritis
Stock to Watch: Array Biopharma Up 7.6% (ARRY)
Comtex SmarTrend(R) - Thu Apr 24, 11:40AM CDT
Array Biopharma (NASDAQ:ARRY) is one of today's best performing low-priced stocks, up 7.6% to $4.09 on 1.2x average daily volume. Array Biopharma has traded 2.0 million shares thus far today, vs. average volume of 1.7 million shares per day. The stock has outperformed the Dow (7.6% to the Dow's 0.1%) and outperformed the S&P 500 (7.6% to the S&P's 0.3%) during today's trading.
Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2014 On April 29, 2014
PR Newswire - Wed Apr 23, 5:30PM CDT
Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2014 and hold a conference call to discuss those results on Tuesday, April 29, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.
Binimetinib Continues To Advance In Clinical Development
PR Newswire - Wed Apr 23, 12:22PM CDT
Following the recent announcement by Novartis and GlaxoSmithKline that they have entered into a definitive agreement to exchange certain assets, Array BioPharma Inc. (NASDAQ: ARRY) reports that Novartis has indicated that it will continue to honor its obligations under the Array-Novartis agreement relating to binimetinib (MEK162), including obligations relating to support for ongoing clinical trials as specified in the agreement.
Investors look to Lighten Up on Shares of Array Biopharma, Shares Down 7.2% (ARRY)
Comtex SmarTrend(R) - Tue Apr 15, 12:48PM CDT
Array Biopharma (NASDAQ:ARRY) is one of today's worst performing low-priced stocks, down 7.2% to $3.47 on 1.0x average daily volume. Array Biopharma has traded 1.6 million shares thus far today, vs. average volume of 1.6 million shares per day. The stock has underperformed the Dow (-7.2% to the Dow's -0.2%) and underperformed the S&P 500 (-7.2% to the S&P's -0.2%) during today's trading.
Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfizer, Cytokinetics, Portola Pharmaceuticals, Volcano, and Array BioPharma
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Cytokinetics, Incorporated (NASDAQ: CYTK), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), Volcano Corporation (NASDAQ: VOLC), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Hot Stock: Array Biopharma, Shares Drop 5.7% (ARRY)
Comtex SmarTrend(R) - Fri Apr 04, 12:45PM CDT
Array Biopharma (NASDAQ:ARRY) is one of today's worst performing low-priced stocks, down 5.7% to $4.14 on 1.2x average daily volume. Thus far today, Array Biopharma has traded 1.8 million shares, vs. average volume of 1.4 million shares per day. The stock has underperformed the Dow (-5.7% to the Dow's -0.5%) and underperformed the S&P 500 (-5.7% to the S&P's -0.8%) during today's trading.
Biotech Stocks Analysis -- Research on Array BioPharma, ACADIA Pharma, Pharmacyclics, and Isis Pharma
PR Newswire - Fri Mar 28, 5:40AM CDT
On Wednesday, March 26, 2014, the NASDAQ Composite ended at 4,173.58, down 1.43%, the Dow Jones Industrial Average fell 0.60% to 16,268.99, and the S&P 500 closed at 1,852.56, down 0.70%. The losses were broad based as nine out of 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 672.05, up 0.05%, and the same has gained 4.63% in the last three months. Investor-Edge has initiated coverage on the following equities: Array BioPharma Inc. (NASDAQ: ARRY), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free technical research on ARRY, ACAD, PCYC and ISIS can be downloaded upon signing up at:
Stock to Watch: Array Biopharma Down 5.2% (ARRY)
Comtex SmarTrend(R) - Thu Mar 27, 12:46PM CDT
Array Biopharma (NASDAQ:ARRY) is one of today's worst performing low-priced stocks, down 5.2% to $4.54 on 1.3x average daily volume. Array Biopharma has traded 1.7 million shares thus far today, vs. average volume of 1.3 million shares per day. The stock has underperformed the Dow (-5.2% to the Dow's -0.1%) and underperformed the S&P 500 (-5.2% to the S&P's -0.3%) during today's trading.
Price Movements, Clinical Trial Results, and Solid Financial Reports - Analyst Notes on Pfizer, Dendreon, DepoMed, Globus Medical, and Array
PR Newswire - Wed Mar 05, 12:13PM CST
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Dendreon Corp. (NASDAQ: DNDN), DepoMed Inc. (NASDAQ: DEPO), Globus Medical, Inc. (NYSE: GMED), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with TDM-1 in Patients with Metastatic HER2+ Breast Cancer
PR Newswire - Thu Feb 20, 7:00AM CST
Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla® (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.
